Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine.

@article{Sullivan2010AdvancesIT,
  title={Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine.},
  author={Seth J. Sullivan and Robert M. Jacobson and Gregory A. Poland},
  journal={Expert review of vaccines},
  year={2010},
  volume={9 10},
  pages={1127-33}
}
On 23 December 2009, the US FDA approved Fluzone® High Dose, a high-dose formulation of the trivalent inactivated influenza vaccine, for prevention of influenza in people 65 years of age and older. As it was approved via an accelerated process designed to allow expeditious availability of safe and effective products with promise to treat or prevent serious or life-threatening diseases, the manufacturer is required to conduct further studies to demonstrate effectiveness. Although these studies… CONTINUE READING